EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hyperuricemia in Chronic Kidney Disease: Emerging Pathophysiology and a Novel Therapeutic Strategy

Tomoaki Takata iD, Yukari Mae, Shotaro Hoi, Takuji Iyama, Hajime Isomoto

International Journal of Molecular Sciences · 16.09.2025 · 26 (18) · 9000

DOI: 10.3390/ijms26189000 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 16.09.2025. Verfasst von Tomoaki Takata und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8504, Japan. Hauptthemen laut MEDLINE: Hyperuricemia, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperuricemia has been increasingly recognized as a modifiable contributor to chronic kidney disease (CKD) progression. Although the traditional classification of hyperuricemia distinguished between renal underexcretion and renal overload types, recent studies suggest that hyperuricemia in patients with CKD can result from heterogeneous excretory defects, including glomerular under-filtration and tubular over-reabsorption. These distinct phenotypes may drive divergent renal injury mechanisms. Experimental and clinical data reveal that monosodium urate crystals and soluble uric acid independently induce renal damage through oxidative stress, inflammasome activation, and endothelial dysfunction. Furthermore, clinical investigations showed inconsistent associations between serum uric acid levels and renal outcomes, suggesting that serum levels alone may not fully reflect urate-related renal risk. This has prompted increasing interest in uricosuric agents, particularly the selective urate reabsorption inhibitors (SURIs), which target tubular urate handling. Urate transporter 1 inhibitors have shown promise in enhancing urinary uric acid excretion and potentially preserving kidney function, especially in patients with CKD. In this review, we summarize the current evidence linking the emerging pathophysiological classification of hyperuricemia, mechanisms or urate-induced kidney injury, and therapeutic interventions. These insights may inform individualized approaches to urate-lowering therapy in CKD and support future research into phenotype-guided treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaRenal Insufficiency, ChronicHumansUric AcidAnimalsUricosuric Agents

Stichwörter der Autor:innen

CKDSURIURAT1glomerular under-filtrationhyperuricemiarenal underexcretiontubular over-reabsorptionurate excretionuric aciduricosuric drug

Substanzen

Uric AcidUricosuric Agents

Autor:innen und Institutionen

  • Division of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Yonago, Tottori 683-8504, Japan.

ORCID-Profile: Tomoaki Takata

Zitieren

APA

Takata, T., Mae, Y., Hoi, S., Iyama, T., & Isomoto, H. (2025). Hyperuricemia in Chronic Kidney Disease: Emerging Pathophysiology and a Novel Therapeutic Strategy. International Journal of Molecular Sciences, 26(18), 9000. https://doi.org/10.3390/ijms26189000

Vancouver

Takata T, Mae Y, Hoi S, Iyama T, Isomoto H. Hyperuricemia in Chronic Kidney Disease: Emerging Pathophysiology and a Novel Therapeutic Strategy. International Journal of Molecular Sciences. 2025;26(18):9000. doi:10.3390/ijms26189000

BibTeX
@article{Takata2025,
  author = {Takata, Tomoaki and Mae, Yukari and Hoi, Shotaro and Iyama, Takuji and Isomoto, Hajime},
  title = {Hyperuricemia in Chronic Kidney Disease: Emerging Pathophysiology and a Novel Therapeutic Strategy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {18},
  pages = {9000},
  doi = {10.3390/ijms26189000}
}
Kostenlos starten →